263 related articles for article (PubMed ID: 21345300)
1. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis.
Lamot L; Bukovac LT; Vidovic M; Frleta M; Harjacek M
Clin Exp Rheumatol; 2011; 29(1):131-9. PubMed ID: 21345300
[TBL] [Abstract][Full Text] [Related]
2. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
Lahdenne P; Vähäsalo P; Honkanen V
Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
[TBL] [Abstract][Full Text] [Related]
3. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.
Katsicas MM; Russo RA
Clin Exp Rheumatol; 2005; 23(4):545-8. PubMed ID: 16095128
[TBL] [Abstract][Full Text] [Related]
4. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Nerome Y; Imanaka H; Nonaka Y; Takei S
Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
[TBL] [Abstract][Full Text] [Related]
5. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
Pratsidou-Gertsi P; Trachana M; Pardalos G; Kanakoudi-Tsakalidou F
Clin Exp Rheumatol; 2010; 28(6):919-22. PubMed ID: 21205467
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
[TBL] [Abstract][Full Text] [Related]
7. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis.
Tynjälä P; Lahdenne P; Vähäsalo P; Kautiainen H; Honkanen V
Ann Rheum Dis; 2006 Aug; 65(8):1044-9. PubMed ID: 16449314
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis.
Hugle B; Burgos-Vargas R; Inman RD; O'Shea F; Laxer RM; Stimec J; Whitney-Mahoney K; Duvnjak M; Anderson M; Tse SM
Clin Exp Rheumatol; 2014; 32(3):424-31. PubMed ID: 24387974
[TBL] [Abstract][Full Text] [Related]
9. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
10. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
11. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
12. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
13. [Biological therapy treatment of juvenile idiopathic arthritis].
Herlin T
Ugeskr Laeger; 2008 Jun; 170(24):2105-8. PubMed ID: 18565289
[TBL] [Abstract][Full Text] [Related]
14. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.
Greenberg JD; Reed G; Decktor D; Harrold L; Furst D; Gibofsky A; Dehoratius R; Kishimoto M; Kremer JM;
Ann Rheum Dis; 2012 Jul; 71(7):1134-42. PubMed ID: 22294625
[TBL] [Abstract][Full Text] [Related]
15. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Windschall D; Horneff G
Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
Quartier P; Taupin P; Bourdeaut F; Lemelle I; Pillet P; Bost M; Sibilia J; Koné-Paut I; Gandon-Laloum S; LeBideau M; Bader-Meunier B; Mouy R; Debré M; Landais P; Prieur AM
Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
20. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ;
J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
